Navigation Links
Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
Date:2/17/2012

EAST BRUNSWICK, N.J., Feb. 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 8:30 AM Eastern Time.  The conference will be held at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact: Mary Coleman

Carney NoensieSavient Pharmaceuticals, Inc.

Burns McClellaninformation@savient.com  

cnoensie@burnsmc.com(732) 418-9300

(212) 213-0006 


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
2. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
3. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
4. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
5. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
6. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
8. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
9. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
10. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
11. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away with ... platform is described by Forbes as "entering the life ... Medical Association as teaching "empathy to medical professionals in ... startup was recently named a finalist for the Department ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Hammer Strength, the world’s leading performance strength training ... of the Houston Rockets the NBSCA Strength & Conditioning Coach of the Year. ... members who vote to select the coach who embodies the highest level of excellence ...
(Date:6/27/2017)... ... 27, 2017 , ... A+ Orthodontics is now offering special ... on treating alignment and occlusion irregularities. Treatment often includes the use of braces ... Hollywood dentist , Dr. Garemani, along with Dr. Reza and the rest of ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Children’s National ... Children’s Hospitals rankings, with its Neonatology program ranking #1 out of more than ... also named to the coveted Honor Roll, a distinction given to the top performing ...
(Date:6/26/2017)... ... ... Antoine Dental Center is now offering various types of dental implants to restore ... support for prosthetic teeth, such as crowns, bridges, or dentures. An implant is placed directly ... new root for the tooth. , Several types of dental implants are available, including: ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):